In the meta-analysis by Hope et al. [26] using histopathology a gold standard, the detection rate of PET/CT with 68Ga-PSMA-targeted agents was 63% in BR-PCa patients with a PSA less than 2.0 ng/mL and 94% in BR-PCa patients with a PSA greater than 2.0 ng/mL. The gene discussed is FOLH1; the disease is posterior cortical atrophy.